Table 3.
Main complications identified in ABX + group and ABX- group
| Identified complication |
Number of patients (%) ABX + group |
Number of patients (%) ABX- group |
p-value |
|---|---|---|---|
| Cutaneous | 118 (34.2%) | 17 (3.6%) | < 0.0001* |
| Respiratory | 98 (28.4%) | 13 (2.8%) | < 0.0001* |
| Hematological | 91 (26.4%) | 74 (15.9%) | 0.0003* |
| Neurological | 37 (10.7%) | 108 (23.2%) | < 0.0001* |
| Hepatological | 20 (5.8%) | 28 (6.0%) | 0.89 |
| Others | 63 (18.2%) | 53 (11.4%) | 0.005* |
*Data with statistical significance. To compare proportions or categorical outcomes chi-squared test or Fisher’s exact test (when appropriate) were performed